Gynecologist-obstetrician, Dr. Patrice Mathevet is an expert in gynecological cancers and more particularly in the surgical treatment of pelvic cancers. He was appointed full professor of UNIL and chief physician of the Department of Gynecology of CHUV from 1 October 2013.

Born in 1960, Dr. Mathevet completed his degree in medicine and biology at the University Claude Bernard Lyon. He obtained his qualification as a specialist in gynecology-obstetrics (1990), which he completed with a certificate of methods in research clinical and epidemiological (1991) and a Master of Human Biology (1991). A stay at the MD Anderson Cancer Center in Houston (USA) as Visiting Professor Assistant (1992-1993) allowed him to work on carcinogenesis in relation to human papillomaviruses. Back in Lyon, he went on to a diploma of advanced studies (DEA) in differentiation, genetics and immunology (1994) and a doctorate of science (2002), while practicing as a hospital practitioner in the Department of Prof. Dargent at the Edouard Herriot Hospital in Lyon.

The scientist joined Lausanne in December 2012 as a visiting professor at UNIL and as head doctor at the Department of Gynecology at the CHUV, before being nominated for the title of UNIL regular professor and head of the Department of Gynecology at the CHUV. from 1 October 2013.

Dr. Mathevet brings with him his vast network of collaborations in Europe (Lyon, Paris, Genoa, Milan, Brussels) and North America (New York, Houston, Quebec).

Clinically, Patrice Mathevet is an expert in the surgical management of pelvic and cervical cancers. He has developed innovative laparoscopic techniques (laparoscopy and trachelectomy) aimed at preserving the fertility of young patients and reducing the effects of treatment. To fight against this same pathology, Patrice Mathevet also worked on the development of a preventive vaccine against the papillomavirus. The therapeutic vaccine is at a promising stage of research.

Her research focuses on the study and application of the sentinel lymph node technique in the management of early cervical cancer. They aim to reduce morbidity in patients with early cancer, limiting lymph node surgery and preventing recurrence, through a better understanding of the mechanisms of lymph node metastases and especially micro-metastases. The scientist is also interested in the biology of bone metastases in breast cancers and their prevention by bisphosphonates.